Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

Inclusion Criteria:

Patients with LVEF Age >/= 18 and Documented NYHA class I, II and III.
For patients who have received trastuzumab: Persistent LV dysfunction must be present 90 days after discontinuation of trastuzumab.
Able to perform 6 minute walk test.
Been treated with appropriate maximal medical therapy for heart failure.
Patient or legally authorized representative able to sign informed consent.

Exclusion Criteria:

Evidence of Ischemic Heart Disease as determined by study cardiologist.
Significant Valvular Disease. (AS with AVA <1.5 and severe AR and MR)
History of Familial Cardiomyopathy.
Recent documented myocarditis within 2 months of enrollment.
History of Infiltrative cardiomyopathy or restrictive cardiomyopathy.
Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram.
Liver function tests > 3 x upper limit of normal.
NYHA class IV heart failure.
Inotropic dependence.
Unstable or life-threatening arrhythmia.
For patients not on anticoagulants, INR>1.5
Mechanical or Bioprosthetic heart valve.
Cardiogenic shock.
Breastfeeding and/or pregnant women.
Autoimmune disorders on current immunosuppressive therapy.
Active infection not responding to appropriate therapy as determined by Study Chair.
Trastuzumab treatment within the last 3 months.
Automatic implantable cardioverter defibrillator (AICD) placement within the last 30 days.
AICD firing within the last 30 days.